1-3 of 3
Haodong Cai
Close
Sort by
Journal Articles

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Clinical Trials & Observations
Di Wang, Jue Wang, Guang Hu, Wen Wang, Yi Xiao, Haodong Cai, Lijun Jiang, Li Meng, Yongkun Yang, Xiaoxi Zhou, Zhenya Hong, Zheng Yao, Min Xiao, Liting Chen, Xia Mao, Li Zhu, Jin Wang, Lugui Qiu, Chunrui Li, Jianfeng Zhou
Journal: Blood
Blood (2021) 137 (21): 2890–2901.
https://doi.org/10.1182/blood.2020008936
Published: 2021
Includes: Supplemental data
Journal Articles

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Clinical Trials & Observations
Na Wang, Xuelian Hu, Wenyue Cao, Chunrui Li, Yi Xiao, Yang Cao, Chaojiang Gu, Shangkun Zhang, Liting Chen, Jiali Cheng, Gaoxiang Wang, Xiaoxi Zhou, Miao Zheng, Xia Mao, Lijun Jiang, Di Wang, Qiuxiang Wang, Yaoyao Lou, Haodong Cai, Dandan Yan, Yicheng Zhang, Tongcun Zhang, Jianfeng Zhou, Liang Huang
Journal: Blood
Blood (2020) 135 (1): 17–27.
https://doi.org/10.1182/blood.2019000017
Published: 2020
Includes: Supplemental data
Journal Articles

Droplet Digital PCR Monitoring of TP53 Mutated Circulating Tumor DNA Levels in Lymphoma Patients

Xiaolu Long, Jia Gu, Yaoyao Lou, Qian Xu, Haodong Cai, MD, Wei Zhang, MD, Kefeng Shen, Min Xiao, MD PhD, Yicheng Zhang, MD PhD, Liting Chen, PhD, Jianfeng Zhou, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4106.
https://doi.org/10.1182/blood-2018-99-113825
Published: 2018